UCB - United Community Banks, Inc.
United Community Banks, Inc. is upgraded from Hold to a soft Buy as transformation efforts and core growth gain traction. Q2 2026 saw net interest income rise to $270.7M, with robust asset quality and return metrics exceeding peers. Strategic divestiture of non-core equipment finance and the Peach State Bank & Trust acquisition enhance capital, liquidity, and regional growth.
United Community Banks NYSE: UCB reported higher second-quarter operating earnings and revenue, while executives said loan growth is accelerating as the company shifts focus back to its core banking franchise following the pending sale of Navitas.
United Community Banks, Inc. (UCB) Q2 2026 Earnings Call Transcript
While the top- and bottom-line numbers for United Community Banks (UCB) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
United Community Banks (UCB) came out with quarterly earnings of $0.71 per share, missing the Zacks Consensus Estimate of $0.8 per share. This compares to earnings of $0.66 per share a year ago.
Strong Loan Growth, Sixth Consecutive Quarter of Margin Expansion, and Focus on Core Banking Business Drive Quarterly Results Strong Loan Growth, Sixth Consecutive Quarter of Margin Expansion, and Focus on Core Banking Business Drive Quarterly Results
I initiate UCB SA with a Buy rating, citing its successful pivot to high-growth immunology and neurology platforms. Bimzelx is the principal growth engine for UCBJY, with €2.23bn 2025 sales and multi-indication approvals driving robust operating leverage. Portfolio diversification via Fintepla, Rystiggo, and Zilbrysq offsets legacy erosion, while recent acquisitions add long-term optionality.
United Community Banks (NYSE: UCB - Get Free Report) and Chesapeake Financial Shares (OTCMKTS:CPKF - Get Free Report) are both finance companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation. Analyst Ratings This is a breakdown
United Community Banks (UCB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GREENVILLE, S.C., July 10, 2026 (GLOBE NEWSWIRE) -- United Community Banks, Inc. (NYSE: UCB) (“United”) and Peach State Bancshares, Inc. (“Peach State”) announced today the election deadline by which Peach State shareholders of record may elect the form of consideration that they prefer to receive as merger consideration pursuant to the Agreement and Plan of Merger, dated as of April 20, 2026, by and between United and Peach State (the “Merger Agreement”). The election deadline is 5:00 p.m. Eastern Time on July 20, 2026. United and Peach State also announced that United has received all required regulatory approvals to acquire Peach State and that the closing of the transaction is expected to occur on August 3, 2026, subject to the satisfaction or waiver of the remaining closing conditions set forth in the Merger Agreement, including the approval of Peach State shareholders.
GREENVILLE, S.C., June 30, 2026 (GLOBE NEWSWIRE) -- United Community Banks, Inc. (NYSE: UCB) announces it will release its second quarter 2026 financial results on Tuesday, July 21, 2026, before the stock market opens. The company also will hold a conference call at 9:00 a.m. EDT on Tuesday, July 21, 2026, to discuss its financial results, business highlights, and outlook.
Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.1 Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression2 and highlights the benefits of early diagnosis.3 ATLANTA, June 17, 2026 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the publication of two manuscripts in Brain Communications. One manuscript reports integrated safety and efficacy findings for KYGEVVI® (doxecitine and doxribtimine), the first and only approved treatment for adults and pediatric patients with early-onset thymidine kinase 2 deficiency (TK2d) with a symptom onset on or before 12 years of age, demonstrating improved survival and functional outcomes in treated patients, along with acceptable tolerability.1 A second manuscript features findings from the largest published dataset of untreated patients with TK2d, illustrating the progressive burden of disease and increased risk of early death, thus reinforcing the importance of timely diagnosis and treatment.2 "TK2d can have a devastating impact on patients and families if left untreated, which the data compiled and published in Brain Communications confirm," said Caterina Garone, Associate Professor of Medical Genetics, University of Bologna, Italy, and co-author of both studies.
United Community Banks, Inc. (UCB) M&A Call Transcript
NEW YORK, June 12, 2026 /PRNewswire/ -- Wafra Inc. ("Wafra"), the $30bn New York-based alternative asset manager, announced today that investment funds advised by Wafra have entered into a definitive agreement to acquire Navitas Credit Corp. ("Navitas"), an industry leader in equipment finance solutions, from United Community Bank, a wholly-owned subsidiary of United Community Banks, Inc. (NYSE: UCB) ("United") for approximately $1.9 billion in cash.1 Navitas will continue to be led by its current management team following the closing of the transaction. Founded in 2008, Navitas specializes in financing essential equipment purchases for small and mid-sized businesses.
GREENVILLE, S.C., June 12, 2026 (GLOBE NEWSWIRE) -- United Community Banks, Inc. (NYSE: UCB) (“United”) today announced the execution of a definitive agreement to sell its equipment finance business, consisting of Navitas Credit Corp. and NLFC Reinsurance Corp. (collectively, “Navitas”), to funds managed by Wafra Inc., acting through Navitas TopCo LLC (“Wafra”) for $1.9 billion in cash1 (the “Transaction”).
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
Steroid use reduction and disease control: In additional results from the Phase 3 PHOENYCS GO study, dapirolizumab pegol (DZP) plus standard of care was associated with sustained disease control at lower glucocorticoid doses through Week 48 compared with placebo plus standard of care, supporting reduced long-term steroid exposure Reduced flare rates and immune marker improvements: In other findings presented at EULAR 2026, improvements in immunological markers and reduced flare rates were observed, supporting the potential of dapirolizumab pegol to address the complex burden of SLE BRUSSELS, Belgium and CAMBRIDGE, Mass.
GREENVILLE, S.C., May 14, 2026 (GLOBE NEWSWIRE) -- United Community Banks, Inc. (NYSE: UCB) (the “Company”), reported that its Board of Directors approved a quarterly cash dividend of $0.25 per share on the Company's common stock. The dividend is payable on July 3, 2026 to shareholders of record as of June 15, 2026.
The deal seeks to bolster the company's pipeline of experimental treatments for autoimmune and inflammatory diseases.
Company to Conduct Nationwide Search for Successor; Harralson to Remain Through Year-end In order to Complete Transition GREENVILLE, S.C., April 28, 2026 /PRNewswire/ -- United Community (NYSE: UCB) today announced that Jefferson Harralson, executive vice president and chief financial officer, is electing to retire after nine years with the company.